Analyzing 1614 cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) cases, researchers found that over 50% of patients traveled more than 100 miles for treatment. While regionalization showed no survival difference, those traveling further had fewer disparities but higher disease severity, raising concerns about access for the underserved, time to treatment, and surgical quality. Median survival didn’t differ based on distance, suggesting regionalization’s appropriateness but emphasizing the need for equitable care and timely intervention for distant-traveling patients.
Journal Article by Solsky I, Patel A (…) Levine EA et 5 al. in Ann Surg Oncol
© 2023. Society of Surgical Oncology.